Dataset Information

TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia.

ABSTRACT:

Purpose

The presence of diffuse anaplasia in Wilms tumours (DAWT) is associated with TP53 mutations and poor outcome. As patients receive intensified treatment, we sought to identify whether TP53 mutational status confers additional prognostic information.

Patients and methods

We studied 40 patients with DAWT with anaplasia in the tissue from which DNA was extracted and analysed for TP53 mutations and 17p loss. The majority of cases were profiled by copy number (n?=?32) and gene expression (n?=?36) arrays. TP53 mutational status was correlated with patient event-free and overall survival, genomic copy number instability and gene expression profiling.

Results

From the 40 cases, 22 (55%) had TP53 mutations (2 detected only after deep-sequencing), 20 of which also had 17p loss (91%); 18 (45%) cases had no detectable mutation but three had 17p loss. Tumours with TP53 mutations and/or 17p loss (n?=?25) had an increased risk of recurrence as a first event (p?=?0.03, hazard ratio (HR), 3.89; 95% confidence interval (CI), 1.26-16.0) and death (p?=?0.04, HR, 4.95; 95% CI, 1.36-31.7) compared to tumours lacking TP53 abnormalities. DAWT carrying TP53 mutations showed increased copy number alterations compared to those with wild-type, suggesting a more unstable genome (p?=?0.03). These tumours showed deregulation of genes associated with cell cycle and DNA repair biological processes.

Conclusion

This study provides evidence that TP53 mutational analysis improves risk stratification in DAWT. This requires validation in an independent cohort before clinical use as a biomarker.

SUBMITTER: Maschietto M

PROVIDER: S-EPMC4196953 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia.

Maschietto Mariana M Williams Richard D RD Chagtai Tasnim T Popov Sergey D SD Sebire Neil J NJ Vujanic Gordan G Perlman Elizabeth E Anderson James R JR Grundy Paul P Dome Jeffrey S JS Pritchard-Jones Kathy K

PloS one 20141014 10

<h4>Purpose</h4>The presence of diffuse anaplasia in Wilms tumours (DAWT) is associated with TP53 mutations and poor outcome. As patients receive intensified treatment, we sought to identify whether TP53 mutational status confers additional prognostic information.<h4>Patients and methods</h4>We studied 40 patients with DAWT with anaplasia in the tissue from which DNA was extracted and analysed for TP53 mutations and 17p loss. The majority of cases were profiled by copy number (n = 32) and gene e ...[more]

PMID: 25313908

Similar Datasets

Project description:TP53 mutations have been associated with anaplasia in Wilms tumour, which conveys a high risk for relapse and fatal outcome. Nevertheless, TP53 alterations have been reported in no more than 60% of anaplastic tumours, and recent data have suggested their presence in tumours that do not fulfil the criteria for anaplasia, questioning the clinical utility of TP53 analysis. Therefore, we characterized the TP53 status in 84 fatal cases of Wilms tumour, irrespective of histological subtype. We identified TP53 alterations in at least 90% of fatal cases of anaplastic Wilms tumour, and even more when diffuse anaplasia was present, indicating a very strong if not absolute coupling between anaplasia and deregulation of p53 function. Unfortunately, TP53 mutations do not provide additional predictive value in anaplastic tumours since the same mutation rate was found in a cohort of non-fatal anaplastic tumours. When classified according to tumour stage, patients with stage I diffuse anaplastic tumours still had a high chance of survival (87%), but this rate dropped to 26% for stages II-IV. Thus, volume of anaplasia or possible spread may turn out to be critical parameters. Importantly, among non-anaplastic fatal tumours, 26% had TP53 alterations, indicating that TP53 screening may identify additional cases at risk. Several of these non-anaplastic tumours fulfilled some criteria for anaplasia, for example nuclear unrest, suggesting that such partial phenotypes should be under special scrutiny to enhance detection of high-risk tumours via TP53 screening. A major drawback is that these alterations are secondary changes that occur only later in tumour development, leading to striking intratumour heterogeneity that requires multiple biopsies and analysis guided by histological criteria. In conclusion, we found a very close correlation between histological signs of anaplasia and TP53 alterations. The latter may precede development of anaplasia and thereby provide diagnostic value pointing towards aggressive disease.

Dataset Information

TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia.

Purpose

Patients and methods

Results

Conclusion

Publications

TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets